Have questions? Contact Us
Novavax’s COVID Vaccine Approved for 24-25 Season!
Great news! Novavax’s COVID vaccine for the 24-24 season has received an EUA approval by the FDA on Friday Aug. 30, 2024. This vaccine is joining ranks with the recent Moderna & Pfizer approvals. The Novavax COVID vaccine, made differently than the mRNA vaccines, is a traditional protein based vaccine. This provides another option for patients 12 years of age and over looking to prevent the more serious potential consequences of a SARS-CoV2 infection. Novavax’s vaccine this season should provide a robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1. The ACIP recommends COVID vaccines to appropriate persons 6 months of age and over, however the Novavax vaccine is currently only for those 12 years and over.
Discounts on COVID vaccines are available to healthcare professionals through a PracticeWell, Physician Buying Group ( PBG ) FREE membership. COVID vaccine savings are available on the Moderna, Pfizer and Novavax brands.